Holen Sie sich die Stockscreener-App
4.58
6.76%
0.29
Handel nachbörslich:
4.63
0.05
+1.09%
Schlusskurs vom Vortag:
$4.29
Offen:
$4.31
24-Stunden-Volumen:
720.19K
Relative Volume:
0.74
Marktkapitalisierung:
$228.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-122.31M
KGV:
-1.0144
EPS:
-4.5151
Netto-Cashflow:
$-110.41M
1W Leistung:
+18.35%
1M Leistung:
-1.93%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.2401
$4.63
1-Wochen-Bereich:
$3.895
$4.63
52-Wochen-Spanne:
$3.76
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Firmenname
Helus Pharma Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare HELP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
4.58 | 212.05M | 0 | -122.31M | -110.41M | -4.5151 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | TD Cowen | Buy |
| 2026-02-02 | Eingeleitet | Jefferies | Buy |
| 2025-03-13 | Eingeleitet | Guggenheim | Buy |
| 2021-11-19 | Herabstufung | Maxim Group | Buy → Hold |
Helus Pharma Inc Aktie (HELP) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
Helus Pharma (Nasdaq: CYBN) to speak at H.C. Wainwright Neuro Perspectives - Stock Titan
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference - Investing News Network
Helus Pharma medical chief in June 15 neuro conference chat - Stock Titan
Helus Pharma: Trump-Dekret beschleunigt HLP003 - Börse Global
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside - Stocktwits
Helus Pharma reports encouraging Phase 2 results for HLP004 anxiety treatment - MSN
Helus Pharma Showcases Mental Health Pipeline at Jefferies Global Healthcare Conference - TipRanks
Cybin (CYBN) showcases Helus Pharma at Jefferies Global Healthcare Conference - Stock Titan
Helus Pharma to Present at Jefferies Global Healthcare Conference Amid Late-Stage Trials for Depression and Anxiety - citybuzz -
Helus Pharma's CEO to speak at Jefferies Global Healthcare Conference on June 4 - Pluang
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York - The Manila Times
Cybin Shares Up Slightly as HELP Backers Focus on Main Trial - Bez Kabli
Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga
HELP Should I Buy - Intellectia AI
Helus Pharma Names Michael Cola As CEO For Next Phase Of Growth - Bernama
Helus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role - MSN
Helus Pharma propels therapeutic innovation in mental health and commences trading on Nasdaq - MSN
Helus Pharma Partners With TARA Mind to Boost Phase 3 Depression Trial in Veterans After U.S. Executive Order - TipRanks
Helus Pharma (Nasdaq: HELP) partners with TARA Mind to boost veteran trial access - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Jefferies reiterates Helus Pharma stock rating on anxiety data - Investing.com
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - The Manila Times
Cybin Inc. will Change its Name to Helus Pharma - marketscreener.com
Helus turns to TARA Mind to reach veterans for depression trial - Stock Titan
Helus Pharma CEO to Spotlight Mental Health Innovation at 29th Milken Global Conference - TipRanks
Helus Pharma (CYBN) interim CEO to join Milken Global Conference health innovation panel - Stock Titan
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference - The Manila Times
A Milken health-innovation panel will feature Helus Pharma's interim CEO - Stock Titan
Helus Pharma Partners With TARA Mind to Boost Phase 3 Trial Recruitment for Major Depressive Disorder in Veterans - citybuzz -
Helus Pharma Aligns With U.S. Veteran Mental Health Push in New TARA Mind Partnership - TipRanks
Cybin (CYBN) Helus Pharma joins TARA Mind to boost HLP003 Phase 3 veteran trial - Stock Titan
Helus Pharma partners with TARA Mind for trial recruitment By Investing.com - Investing.com South Africa
Helus Pharma partners with TARA Mind for trial recruitment - Investing.com
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health - ChartMill
HELP | Cybin Inc. Common Stock Insider Trading - Quiver Quantitative
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk? - Yahoo Finance
Finanzdaten der Helus Pharma Inc-Aktie (HELP)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):